{
  "$schema": "https://themachinepress.com/schemas/story-v1.schema.json",
  "schema_version": "1.0.0",
  "document_type": "machine_press_story",
  "story": {
    "story_id": "mp-2026-07-18-003",
    "source_story_id": "tmp-story-dna-delivered-ovarian-bte",
    "edition_id": "mp-2026-07-18-morning-0009",
    "edition_url": "https://themachinepress.com/edition/2026-07-18",
    "position": 3,
    "story_type": "dispatch",
    "section": "research",
    "editorial_classification": "editorial",
    "headline": "Two Tumor Targets Fit Into One DNA-Delivered Dose",
    "slug": "two-tumor-targets-fit-into-one-dna-delivered-dose",
    "dek": "Wistar's preclinical platform makes bispecific T-cell engagers in the body and combines two ovarian-cancer targets.",
    "summary": "Wistar's preclinical platform makes bispecific T-cell engagers in the body and combines two ovarian-cancer targets.",
    "body_text": "Wistar researchers reported a knob-into-hole antibody design delivered as DNA, allowing cells to produce bispecific T-cell engagers after dosing. A two-target version is intended to reduce escape when a tumor loses one antigen. The work improved ovarian-cancer control in preclinical models; it is not evidence of safety or benefit in patients.",
    "why_it_matters": "Wistar's preclinical platform makes bispecific T-cell engagers in the body and combines two ovarian-cancer targets.",
    "limitations": [
      "The work improved ovarian-cancer control in preclinical models; it is not evidence of safety or benefit in patients."
    ],
    "importance": 9,
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-18-003/two-tumor-targets-fit-into-one-dna-delivered-dose",
    "json_url": "https://themachinepress.com/story/mp-2026-07-18-003.json",
    "first_published_at": "2026-07-18T09:00:00.000-04:00",
    "modified_at": "2026-07-18T09:00:00.000-04:00",
    "content_status": "new",
    "is_carryover": false,
    "carryover_reason": null,
    "key_claims": [
      {
        "claim_id": "claim-mp-2026-07-18-003-001",
        "text": "Wistar's preclinical platform makes bispecific T-cell engagers in the body and combines two ovarian-cancer targets.",
        "source_ids": [
          "source-2026-07-18-003"
        ],
        "qualification": "The work improved ovarian-cancer control in preclinical models; it is not evidence of safety or benefit in patients."
      }
    ],
    "source_ids": [
      "source-2026-07-18-003"
    ],
    "tags": [
      "ovarian cancer",
      "immunotherapy",
      "bispecific antibodies"
    ],
    "image_url": "https://themachinepress.com/issues/2026-07-18/wistar-immunotherapy-file-image.webp",
    "corrections": []
  },
  "sources": [
    {
      "source_id": "source-2026-07-18-003",
      "title": "Wistar via Newswise: DNA-delivered ovarian cancer immunotherapy",
      "publisher": "The Wistar Institute via Newswise",
      "url": "https://www.newswise.com/articles/wistar-scientists-develop-dna-delivered-immunotherapy-that-targets-ovarian-cancer-more-effectively",
      "canonical_url": "https://www.newswise.com/articles/wistar-scientists-develop-dna-delivered-immunotherapy-that-targets-ovarian-cancer-more-effectively",
      "source_type": "official_announcement",
      "is_primary_source": true,
      "published_at": "2026-07-17T18:30:00.000-04:00",
      "accessed_at": "2026-07-18T08:25:00.000-04:00",
      "supports_claim_ids": [
        "claim-mp-2026-07-18-003-001"
      ]
    }
  ],
  "corrections": [],
  "publisher": {
    "name": "The Machine Press",
    "url": "https://themachinepress.com",
    "description": "A daily newspaper for the age of artificial intelligence."
  },
  "cite_this_report": {
    "title": "Two Tumor Targets Fit Into One DNA-Delivered Dose",
    "publisher": "The Machine Press",
    "published_at": "2026-07-18T09:00:00.000-04:00",
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-18-003/two-tumor-targets-fit-into-one-dna-delivered-dose"
  }
}